Cancer News and Stories
Our team of experts brings you cancer-related news, features, and survivor stories.
For the latest news about research we conduct and fund, see ACS Research News.
Filtering by:
Targeted TherapyTargeted Drug Trastuzumab Deruxtecan Slows Growth of Metastatic Breast Cancer
Published on: July 26, 2024
A study of the HER2-targeted therapy drug trastuzumab deruxtecan (Enhertu) shows it can stop metastatic breast cancer growth for longer than chemotherapy.
Targeted Drug Stops Lung Cancer Growth for Five Years in Over Half of People with Mutated Lung Cancer
Published on: June 13, 2024
A study shows that a targeted therapy drug stops the spread of lung cancer for 5 years or more. The drug, lorlatinib (Lobrena), also stops new cancer growth in the brain.
Targeted Cancer Drug Lowers Risk of Cancer Growth or Death in Lung Cancer with a Specific Mutation
Published on: June 13, 2024
A study has shown that giving patients with lung cancer a targeted therapy drug after combined chemotherapy and radiation therapy helps them live longer without the cancer growing or spreading.
Recent Advances in Lung Cancer Treatment Resulting in Lower Death Rates
Published on: August 17, 2020
According to a new study, death rates from non-small cell lung cancer have fallen sharply in recent years, mostly due to advances in treatment.
FDA Approves Trodelvy (Sacituzumab govitecan-hziy) for Triple Negative Breast Cancer
Published on: April 29, 2020
The US Food and Drug Administration (FDA) approved a new type of therapy for triple-negative breast cancer that has spread to other parts of the body and hasn’t responded to other treatments.
FDA Approves Pemazyre (Pemigatinib) for Bile Duct Cancer
Published on: April 22, 2020
The US Food and Drug Administration (FDA) approved the first targeted therapy for bile duct cancer. Pemazyre (pemigatinib) is for adults whose cancer has grown after at least one previous chemotherapy treatment and whose tumors have a mutation in the FGFR2 gene.
FDA Approves Tazverik (Tazemetostat) for Epithelioid Sarcoma
Published on: January 24, 2020
The US Food and Drug Administration (FDA) has approved Tazverik (tazemetostat) to treat adults and children 16 and older with epithelioid sarcoma, a rare cancer which accounts for less than 1% of all soft tissue sarcomas.
FDA Approves Ayvakit (Avapritinib) for GIST
Published on: January 10, 2020
The US Food and Drug Administration (FDA) has approved Ayvakit (avapritinib) to treat people with advanced cases of gastrointestinal stromal tumor (GIST) that have a certain genetic mutation.
